Meloxicam modulates oxidative stress status, inhibits prostaglandin E2, and abrogates apoptosis in carbon tetrachloride-induced rat hepatic injury

International Journal of Toxicology

Volumn 31, Issue 3, 2012, Pages 276-286

  Edfawy, Mohamed ^a   Hassan, Memy H ^b,c   Mansour, Ahmed ^b   Hamed, Abdel Aziz ^b   Amin, Hebat Allah A ^d  

^a Egyptian Russian University   (Egypt)

^b Al Azhar University   (Egypt)

^c TAIBAH UNIVERSITY   (Saudi Arabia)

^d MINISTRY OF JUSTICE   (Egypt)

Author keywords

carbon tetrachloride; cycloxegenase 2; meloxicam; oxidative stress

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; CARBON TETRACHLORIDE; CATALASE; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; GLUTATHIONE; GLUTATHIONE TRANSFERASE; MALONALDEHYDE; MELOXICAM; PROSTAGLANDIN E2; SUPEROXIDE DISMUTASE;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; APOPTOSIS; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; CONTROLLED STUDY; ENZYME INHIBITION; HISTOLOGY; LIPID PEROXIDATION; LIVER CELL; LIVER FUNCTION; LIVER INJURY; LIVER TOXICITY; MALE; NONHUMAN; OXIDATIVE STRESS; RAT;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; APOPTOSIS; CARBON TETRACHLORIDE; CASPASE 3; CYCLOOXYGENASE 2 INHIBITORS; DINOPROSTONE; DRUG-INDUCED LIVER INJURY; GLUTATHIONE; MALE; MALONDIALDEHYDE; OXIDATIVE STRESS; PROTECTIVE AGENTS; RATS; RATS, SPRAGUE-DAWLEY; THIAZINES; THIAZOLES;

RATTUS;

EID: 84862013891     PISSN: 10915818     EISSN: 1092874X     Source Type: Journal    
DOI: 10.1177/1091581812442939     Document Type: Article

References (78)

1. Basu S. Carbon tetrachloride-induced lipid peroxidation: eicosanoid formation and their regulation by antioxidant nutrients. Toxicol. 2003;189(1-2):113-127. (Pubitemid 36725027)
2. Hardin BL. Carbon tetrachloride poisoning; a review. Ind Med Surg. 1954;23(3):93-105.
3. Bacon BR, Tavill AS, Brittenham GM, Park CH, Recknagel RO. Hepatic lipid peroxidation in vivo in rats with chronic iron overload. J Clin Invest. 1983;71(3):429-439. (Pubitemid 13160788)
4. Brattin WJ, Glende EA, Recknagel RO. Pathological mechanisms in carbon tetrachloride hepatotoxicity. J Free Radic Biol Med. 1985;1(1):27-38. (Pubitemid 16104819)
5. Weber LW, Boll M, Stampfl A. Hepatotoxicity and mechanism of action of haloalkanes: carbon tetrachloride as a toxicological model. Crit Rev Toxicol. 2003;33(2):105-136. (Pubitemid 36432872)
6. Ismail RS, El-Megeid AA, Abdel-Moemin AR. Carbon tetrachloride-induced liver disease in rats: the potential effect of supplement oils with vitamins E and C on the nutritional status. Ger Med Sci. 2009;7:1612-3174.
7. Chiu PY, Tang MH, Mak DH, Poon MK, Ko KM. Hepatoprotective mechanism of schisandrin B: role of mitochondrial glutathione antioxidant status and heat shock proteins. Free Radic Biol Med. 2003;35(4):368-380. (Pubitemid 37289167)
8. Pietta PG. Flavonoids as antioxidants. J Nat Prod. 2000;63(7):1035-1042.
9. Singh U, Devaraj S, Jialal I. Vitamin E, oxidative stress, and inflammation. Annu Rev Nutr. 2005;25:151-174. (Pubitemid 41208998)
10. Garcia-Ruiz C, Fernandez-Checa JC. Redox regulation of hepatocyte apoptosis. J Gastroenterol Hepatol. 2007;22(suppl 1):S38-S42. (Pubitemid 46848988)
11. Ozben T. Oxidative stress and apoptosis: impact on cancer therapy. J Pharm Sci. 2007;96(9):2181-2196. (Pubitemid 47477879)
12. Yen FL, Wu TH, Lin LT, Cham TM, Lin CC. Naringenin-loaded nanoparticles improve the physicochemical properties and the hepatoprotective effects of naringenin in orally-administered rats with CCl(4)-induced acute liver failure. PharmRes. 2009;26(4):893-902.
13. Clària J. Cyclooxygenase-2 biology. Curr Pharm Des. 2003;9(27):2177-2190. (Pubitemid 37139092)
14. Vane JR. COX-2 inhibitors: background knowledge for clinical use. Introduction. Inflamm Res. 1988;47(suppl 2):S77.
15. Planaguma A, Claria J, Miquel R, et al. The selective cyclooxygenase-2 inhibitor SC-236 reduces liver fibrosis by mechanisms involving non-parenchymal cell apoptosis and PPARgamma activation. FASEB J. 2005;19(9):1120-1122. (Pubitemid 40946437)
16. Cheng AS, Chan HL, Leung WK, et al. Expression of HBx and COX-2 in chronic hepatitis B, cirrhosis and hepatocellular carcinoma: implication of HBx in upregulation of COX-2. Mod Pathol. 2004;17(10):1169-1179. (Pubitemid 39312943)
17. Nunez O, Fernandez-Martinez A, Majano PL, etal. Increased intrahepatic cyclooxygenase 2, matrix metalloproteinase 2, and matrix metalloproteinase 9 expression is associated with progressive liver disease in chronic hepatitis C virus infection: role of viral core and NS5A proteins. Gut. 2004;53(11):1665- 1672. (Pubitemid 39434113)
18. Nanji AA, Miao L, Thomas P, et al. Enhanced cyclooxygenase-2 gene expression in alcoholic liver disease in the rat. Gastroenterol. 1997;112(3):943-951. (Pubitemid 27113821)
19. Yamamoto H, Kondo M, Nakamori S, et al. JTE-522, a cyclooxygenase-2 inhibitor, is an effective chemopreventive agent against rat experimental liver fibrosis1. Gastroenterol. 2003;125(2):556-571. (Pubitemid 36929437)
20. Mohammed NA, Abd El-Aleem SA, El-Hafiz HA, McMahon RF. Distribution of constitutive (COX-1) and inducible (COX-2) cyclooxygenase in postviral human liver cirrhosis: a possible role for COX-2 in the pathogenesis of liver cirrhosis. J Clin Pathol. 2004;57(4):350-354. (Pubitemid 38446249)
21. 4-treated rat liver injury. J Korean Med Sci. 2002;17(2):193-200.
22. Nanji AA, Zakim D, Rahemtulla A, et al. Dietary saturated fatty acids down-regulate cyclooxygenase-2 and tumor necrosis factor alfa and reverse fibrosis in alcohol-induced liver disease in the rat. Hepatol. 1997;26(6):1538-1545. (Pubitemid 27520020)
23. Wang JL, Cheng HF, Shappell S, Harris RC. A selective cyclooxygenase-2 inhibitor decreases proteinuria and retards progressive renal injury in rats. Kidney Int. 2000;57(6):2334-2342. (Pubitemid 30340732)
24. Han HK, Choi HK. Improved absorption of meloxicam via salt formation with ethanolamines. Eur J Pharm Biopharm. 2007; 65(1):99-103.
25. Pairet M, Engelhardt G. Distinct isoforms (COX-1 and COX-2) of cyclooxygenase: possible physiological and therapeutic implications. Fundam Clin Pharmacol. 1996;10(1):1-17.
26. Gates BJ, Nguyen TT, Setter SM, Davies NM. Meloxicam: a reappraisal of pharmacokinetics, efficacy and safety. Expert Opin Pharmacother. 2005;6(12):2117-2140. (Pubitemid 41600587)
27. Hakan T, Toklu HZ, Biber N, et al. Meloxicam exerts neuroprotection on spinal cord trauma in rats. Int J Neurosci. 2011;121(3):142-148.
28. Kalonia H, Kumar A. Suppressing inflammatory cascade by cyclo-oxygenase inhibitors attenuates quinolinic acid induced Huntington's disease-like alterations in rats. Life Sci. 2011;88(17-18):784-791.
29. Jayasekhar P, Mohanan P, Rathinam K. Hepatoprotective activity of ethyl acetate extract of Acacia catechu. Ind J Pharmacol. 1997;29:426.
30. Sun H, Che QM, Zhao X, Pu XP. Antifibrotic effects of chronic baicalein administration in a CCl4 liver fibrosis model in rats. Eur J Pharmacol. 2010;631(1-3):53-60.
31. Kumar A, Kumari B, Kumar P. Protective effects of selective and non-selective cyclooxygenase inhibitors in an animal model of chronic stress. Neurosci Bull. 2010;26(1):17-27.
32. Bancroft J, Stevens A. Enzyme histochemistry. In: Theory and Practice of Histological Techniques. New York, NY: Churchill Livingstone; 1996.
33. Reitman S, Frankel S. A colorimetric method for the determination of serum glutamic oxalacetic and glutamic pyruvic transaminases. Am J Clin Pathol. 1957;28(1):56-63.
34. Sbrana E, Mateo RI, Xiao SY, Popov VL, Newman PC, Tesh RB. Clinical laboratory, virologic, and pathologic changes in hamsters experimentally infected with Pirital virus (Arenaviridae): a rodent model of Lassa fever. Am J Trop Med Hyg. 2006;74(6):1096-1102. (Pubitemid 351627423)
35. Johnson D, Lardy H. Isolation of liver or kidney mitochondria. Methods Enzymol. 1967;10:94-96.
36. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. Protein measurement with the Folin phenol reagent. J Biol Chem. 1951;193(1):265-275.
37. Marklund S, Marklund G. Involvement of the superoxide anion radical in the autoxidation of pyrogallol and a convenient assay for superoxide dismutase. Eur J Biochem. 1974;47(3):469-474.
38. Sinha AK. Colorimetric assay of catalase. Analyt Biochem. 1972;47(2):389-394.
39. Habig W, Pabst MJ, Jakoby W. Glutathione S-transferases. The first enzymatic step in mercapturic acid formation. J Biol Chem. 1974;249(22):7130.
40. Ohkawa H, Ohishi N, Yagi K. Assay for lipid peroxides in animal tissues by thiobarbituric acid reaction. Analytical Biochem. 1979;95(2):351-358. (Pubitemid 9194347)
41. Moron MS, Depierre JW, Mannervik B. Levels of glutathione, glutathione reductase and glutathione S-transferase activities in rat lung and liver. Biochim Biophys Acta. 1979;582(1):67-78. (Pubitemid 9065588)
42. Krajewska M, Wang HG, Krajewski S, et al. Immunohistochemical analysis of in vivo patterns of expression of CPP32 (Caspase-3), a cell death protease. Cancer Res. 1997;57(8):1605.
43. Yoo JY, Kang SJ, Ahn WS, Kim BK. E-Cadherin expression and p53 alterations in soft tissue sarcomas: a possible role in epithelial differentiation. Cancer Res Treat. 2001;33(4):343-349.
44. Steel RGD, Torrie JH. Principles and Procedures of Statistics: A Biometrical Approach. 2nd ed. NewYork, NY: McGraw-Hill; 1980.
45. Amin A, Hamza AA. Oxidative stress mediates drug-induced hepatotoxicity in rats: a possible role of DNA fragmentation. Toxicol. 2005;208(3):367-375. (Pubitemid 40202835)
46. Dizdaroglu M, Jaruga P, Birincioglu M, Rodriguez H. Free radical-induced damage to DNA: mechanisms and measurement. Free Radic Biol Med. 2002;32(11):1102-1115. (Pubitemid 34603348)
47. Kodai S, Takemura S, Minamiyama Y, et al. S-allyl cysteine prevents CCl4-induced acute liver injury in rats. Free Rad Res. 2007;41(4):489-497. (Pubitemid 46470947)
48. Manibusan MK, Odin M, Eastmond DA. Postulated carbon tetrachloride mode of action: a review. J Environ Sci Health Part C. 2007;25(3):185-209. (Pubitemid 47347112)
49. Kadiiska M, Gladen B, Baird D, et al. Biomarkers of oxidative stress study II: are oxidation products of lipids, proteins, and DNA markers of CCl4 poisoning?. Free Rad Biol Med. 2005;38(6):698-710. (Pubitemid 40249740)
50. Chávez E, Segovia J, Shibayama M, et al. Antifibrotic and fibrolytic properties of celecoxib in liver damage induced by carbon tetrachloride in the rat. Liver Int. 2010;30(7):969-978.
51. Washino Y, Koga E, Kitamura Y, et al. Effect of celecoxib, a selective cyclooxygenase-2 inhibitor on carbon tetrachloride intoxication in rats. Biol Pharm Bull. 2010;33(4):707-709.
52. Yu J, Ip E. COX 2 induction in mice with experimental nutritional steatohepatitis: role as pro inflammatory mediator. Hepatol. 2006;43(4):826-836.
53. Federico A, Morgillo F, Tuccillo C, Ciardiello F, Loguercio C. Chronic inflammation and oxidative stress in human carcinogenesis. Int J Cancer.2007;121(11):2381-2386. (Pubitemid 350022406)
54. Tipoe GL, Leung T, Liong E, et al. Inhibitors of inducible nitric oxide (NO) synthase are more effective than an NO donor in reducing carbon-tetrachloride induced acute liver injury. Histol Histopathol. 2006;21(11):1157-1165. (Pubitemid 44614497)
55. 4)-induced liver injury in mice. Toxicol. 2010;273(1-3):45-52.
56. 4-induced hepatic damage and inflammatory action in rats. J Med Food. 2009;12(4):821-828.
57. Mikami K, Goto T, Miura K, et al. Gabexate mesilate, a synthetic protease inhibitor, attenuates carbon tetrachloride-induced liver injury in rats. J Gastroenterol. 2005;40(3):260-265. (Pubitemid 40613383)
58. 4: an electron microscopy study. Ultrastruct Pathol. 2011;35(1):26-30.
59. Ikeda H, Kume Y, Tejima K, et al. Rho-kinase inhibitor prevents hepatocyte damage in acute liver injury induced by carbon tetrachloride in rats. Am J Physiol Gastrointest Liver Physiol. 2007;293(4):G911-G917. (Pubitemid 47605940)
60. Sun F, Hamagawa E, Tsutsui C, Ono Y, Ogiri Y, Kojo S. Evaluation of oxidative stress during apoptosis and necrosis caused by carbon tetrachloride in rat liver. Biochim Biophys Acta. 2001;1535(2):186-191. (Pubitemid 32112764)
61. Ding WX, Ong NC. Role of oxidative stress and mitochondrial changes in cyanobacteria induced apoptosis and hepatotoxicity. FEMS Microbiol Lett. 2003;220(1):1-7.
62. Pereira CF, Oliveira CR. Oxidative glutamate toxicity involves mitochondrial dysfunction and perturbation of intracellular Ca2+homeostasis. Neurosci Res. 2000;37(3):227-236. (Pubitemid 30625012)
63. Shi J, Aisaki K, Ikawa Y, Wake K. Evidence of hepatocyte apoptosis in rat liver after the administration of carbon tetrachloride. Am J Pathol. 1998;153(2):515-525. (Pubitemid 28373662)
64. Kaplowitz N. Biochemical and cellular mechanisms of toxic liver injury. Semin Liver Dis. 2002;22(2):137-44. (Pubitemid 34496467)
65. Zhang J, Dong M, Li L, et al. Endonuclease G is required for early embryogenesis and normal apoptosis in mice. Proc Natl Acad Sci USA. 2003;100(26):15782-15787. (Pubitemid 38021067)
66. Bajt ML, Vonderfecht SL, Jaeschke H. Differential protection with inhibitors of caspase-8 and caspase-3 in murine models of tumor necrosis factor and Fas receptor-mediated hepatocellular apoptosis. Toxicol Appl Pharmacol. 2001;175(3):243-252. (Pubitemid 32917748)
67. Guicciardi M, Gores G. Apoptosis: a mechanism of acute and chronic liver injury. Gut. 2005;54(7):1024-1033. (Pubitemid 40873921)
68. Riordan SM,Williams R. Mechanisms of Hepatocyte Injury, Multiorgan Failure, and Prognostic Criteria in Acute Liver Failure. New York, NY: Thieme-Stratton; 2003:203-216.
69. Kim SM, Park KC, Kim HG, Han SJ. Effect of selective cyclooxygenase 2 inhibitor meloxicam on liver fibrosis in rats with ligated common bile ducts. Hepatol Res. 2008;38(8):800-809. (Pubitemid 352015631)
70. Liu Q, Kong B, Li G, Liu N, Xia X. Hepatoprotective and antioxidant effects of porcine plasma protein hydrolysates on carbon tetrachloride-induced liver damage in rats. Food Chem Toxicol. 2011;49(6):1316-1321.
71. Gurocak S, Ure I, Cumaoglu A, et al. Renal tissue damage after experimental pyelonephritis: role of anti-oxidants and selective cyclooxygenase-2 inhibitors. Urology. 2010;76(2):508.e1-508.e5.
72. Cimen BM, Cimen BÖ, Eskandari G, Sahin G, Erdogan C, Atik U. In vivo effects of meloxicam, celecoxib, and ibuprofen on free radical metabolism in human erythrocytes. Drug chem Toxicol. 2003;26(3):169-176. (Pubitemid 36951088)
73. Arafa HMM, Abdel-Wahab MH, El-Shafeey MF, Badary OA, Hamada F. Anti-fibrotic effect of meloxicam in a murine lung fibrosis model. Eur J Pharmacol. 2007;564(1-3):181-189. (Pubitemid 46946863)
74. Lu Y,Wahl LM. Oxidative stress augments the production ofmatrix metalloproteinase-1, cyclooxygenase-2, and prostaglandin E2 through enhancement of NF- B activity in lipopolysaccharide-activated human primary monocytes. J Immunol. 2005;175(8):5423-5429. (Pubitemid 41456428)
75. Engelhardt G, Homma D, Schlegel K, Utzmann R, Schnitzler C. Anti-inflammatory, analgesic, antipyretic and related properties of meloxicam, a new non-steroidal anti-inflammatory agent with favourable gastrointestinal tolerance. Inflam Res. 1995;44(10):423-433.
76. Shanmugathasan M, Jothy S. Apoptosis, anoikis and their relevance to the pathobiology of colon cancer. Pathol Int. 2000;50(4):273-279. (Pubitemid 30441278)
77. Soldani C, Scovassi AI. Poly(ADP-ribose) polymerase-1 cleavage during apoptosis: an update. Apoptosis. 2002;7(4):321-328. (Pubitemid 34832256)
78. Bhave VS, Donthamsetty S, Latendresse JR, Mehendale HM. Inhibition of cyclooxygenase-2 aggravates secretory phospholipaseA2-mediated progression of acute liver injury. Toxicol Appl Pharmacol. 2008;228(2):239-246.